The historical rank and industry rank for Gentian Diagnostics AS's FCF Margin % or its related term are showing as below:
OSL:GENT'
s FCF Margin % Range Over the Past 10 Years
Min: -91.41 Med: -32.91 Max: 18.03
Current: 8.33
During the past 13 years, the highest FCF Margin % of Gentian Diagnostics AS was 18.03%. The lowest was -91.41%. And the median was -32.91%.
OSL:GENT's FCF Margin % is ranked better than 69.68% of 818
companies
in the Medical Devices & Instruments industry
Industry Median: -0.375
vs OSL:GENT: 8.33
Gentian Diagnostics AS FCF Margin % Related Terms
Gentian Diagnostics AS FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:GENT vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS (OSL:GENT) has a FCF Margin % of -28.66% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Gentian Diagnostics AS and its competitors. According to the industry distribution chart, Gentian Diagnostics AS ranks #248 out of 818 companies in the Medical Devices & Instruments industry, placing it in the top 30.3%.
Is Gentian Diagnostics AS's FCF Margin % too high?
Gentian Diagnostics AS's current FCF Margin % is -28.66%. Based on the distribution chart, Gentian Diagnostics AS ranks #248 out of 818 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Gentian Diagnostics AS has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #248 out of 818 companies for FCF Margin %. This puts Gentian Diagnostics AS in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current FCF Margin % is -28.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Possible Value Trap. The stock's GF Value™ is kr61.81, compared to a current price of kr37.00 — trading 40.1% below its estimated fair value. The current FCF Margin % is -28.66%. Gentian Diagnostics AS's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current FCF Margin % is -28.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr37.00 is trading 40.1% below its estimated GF Value™ of kr61.81.
GuruFocus considers Gentian Diagnostics AS to be Possible Value Trap.
Key valuation signals for OSL:GENT:
FCF Margin %: -28.66%
GF Value™: kr61.81 vs. price of kr37.00 (40.1% below fair value)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
72GF Score
Get the complete analysis for OSL:GENT
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
